Ardelyx Inc. Insider Trading

ARDX

⊜ Compare

Last 12 months

Insiders bought $1.95M and sold $4.3M on the open market.

54% of the selling was scheduled in advance under 10b5-1 plans.

Net open-market

−$2.36M

1 buy · 38 sales

Under a 10b5-1 plan

54%

of the value sold

Insiders who bought / sold

1 / 9

executives and directors

Last open-market buy

Feb 2026

Feb 20, 2026

Get an email when ARDX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 21	Susan Hohenleitner Chief Financial Officer	SoldNo plan	1,558	$3.86	6K	0.7%	Form 4
Aug 21	James Parker Brady Chief Human Resources Officer	SoldNo plan 2 parts	15,136	$3.86 average	58K	5.8%	Form 4
Aug 21	Joseph James Reilly See Remarks	SoldNo plan 2 parts	3,982	$3.86 average	15K	2.7%	Form 4
Aug 21	Eric Duane Foster Chief Commercial Officer	SoldNo plan 3 parts	8,562	$3.86 average	33K	2.0%	Form 4
Aug 21	Mike Kelliher Chief Business Officer	SoldNo plan 3 parts	7,758	$3.86 average	30K	2.2%	Form 4
Aug 21	Laura A Williams Chief Patient Officer	SoldNo plan 4 parts	10,739	$3.86 average	41K	2.8%	Form 4
Aug 21	Michael Raab President & CEO	SoldNo plan 4 parts	58,574	$3.86 average	226K	3.4%	Form 4
Aug 21	John E Bishop See Remarks	SoldNo plan 2 parts	19,750	$3.86 average	76K	5.9%	Form 4
Jul 15	Michael Raab President & CEO	Sold10b5-1 plan	41,668	$5.06	211K	2.4%	Form 4
Jun 18	Laura A Williams Chief Patient Officer	Sold10b5-1 plan	81,898	$5.99	491K	18%	Form 4
Jun 15	Michael Raab President & CEO	Sold10b5-1 plan	41,666	$5.67	236K	2.4%	Form 4
May 21	Susan Hohenleitner Chief Financial Officer	SoldNo plan	1,455	$6.27	9K	0.6%	Form 4
May 21	James Parker Brady Chief Human Resources Officer	SoldNo plan	1,846	$6.27	12K	0.7%	Form 4
May 21	Joseph James Reilly See Remarks	SoldNo plan 2 parts	3,719	$6.27 average	23K	2.4%	Form 4
May 21	Eric Duane Foster Chief Commercial Officer	SoldNo plan 3 parts	7,998	$6.27 average	50K	1.9%	Form 4
May 21	Mike Kelliher Chief Business Officer	SoldNo plan 3 parts	7,248	$6.27 average	45K	2.0%	Form 4
May 21	Laura A Williams Chief Patient Officer	SoldNo plan 4 parts	6,989	$6.27 average	44K	1.6%	Form 4
May 21	Michael Raab President & CEO	SoldNo plan 4 parts	54,748	$6.27 average	343K	3.0%	Form 4
May 21	John E Bishop See Remarks	SoldNo plan	2,306	$6.27	14K	0.7%	Form 4
May 15	Michael Raab President & CEO	Sold10b5-1 plan	41,666	$6.28	262K	2.3%	Form 4
Apr 15	Michael Raab President & CEO	Sold10b5-1 plan	41,668	$6.29	262K	2.2%	Form 4
Mar 16	Michael Raab President & CEO	Sold10b5-1 plan	41,666	$5.84	243K	2.2%	Form 4
Feb 24	Michael Raab President & CEO	Sold10b5-1 plan	41,666	$6.26	261K	2.2%	Form 4
Feb 20	David M Mott Director	Bought	333,333	$5.84	$1.95M	11%	Form 4
Feb 20	John E Bishop See Remarks	SoldNo plan 3 parts	3,179	$5.85 average	19K	0.9%	Form 4
Feb 20	Joseph James Reilly See Remarks	SoldNo plan 3 parts	4,991	$5.85 average	29K	3.2%	Form 4
Feb 20	Laura A Williams See Remarks	SoldNo plan 2 parts	8,176	$5.85 average	48K	1.8%	Form 4
Feb 20	Susan Hohenleitner Chief Financial Officer	SoldNo plan 2 parts	2,033	$5.85 average	12K	0.9%	Form 4
Feb 20	James Parker Brady Chief Human Resources Officer	SoldNo plan 2 parts	2,543	$5.85 average	15K	1.0%	Form 4
Feb 20	Mike Kelliher See Remarks	SoldNo plan 3 parts	9,595	$5.85 average	56K	2.6%	Form 4
Feb 20	Michael Raab President & CEO	SoldNo plan 5 parts	45,982	$5.85 average	269K	2.4%	Form 4
Feb 20	Eric Duane Foster Chief Commercial Officer	SoldNo plan 4 parts	10,439	$5.85 average	61K	2.4%	Form 4
Jan 8	Laura A Williams Chief Patient Officer	Sold10b5-1 plan	50,000	$6.98	349K	12%	Form 4
Nov 21, 2025	Elizabeth A Grammer See Remarks	SoldNo plan	5,995	$5.54	33K	2.0%	Form 4
Nov 21, 2025	Michael Raab President & CEO	SoldNo plan	46,887	$5.54	260K	3.1%	Form 4
Nov 21, 2025	Mike Kelliher See Remarks	SoldNo plan	5,560	$5.54	31K	2.0%	Form 4
Nov 21, 2025	Laura A Williams Chief Patient Officer	SoldNo plan	6,426	$5.54	36K	1.8%	Form 4
Nov 21, 2025	Eric Duane Foster Chief Commercial Officer	SoldNo plan	5,814	$5.54	32K	1.9%	Form 4
Nov 21, 2025	Joseph James Reilly See Remarks	SoldNo plan	11,086	$5.54	61K	9.2%	Form 4
Aug 26, 2025	Laura A Williams Chief Patient Officer	Sold10b5-1 plan 2 parts	80,000	$6.12 average	490K	18%	Form 4

Aug 21No plan
Susan Hohenleitner
Chief Financial Officer · sold 1,558 at $3.86
6K
0.7% of stake
Aug 21No plan
James Parker Brady
Chief Human Resources Officer · sold 15,136 at avg $3.86
58K
5.8% of stake
Aug 21No plan
Joseph James Reilly
See Remarks · sold 3,982 at avg $3.86
15K
2.7% of stake
Aug 21No plan
Eric Duane Foster
Chief Commercial Officer · sold 8,562 at avg $3.86
33K
2.0% of stake
Aug 21No plan
Mike Kelliher
Chief Business Officer · sold 7,758 at avg $3.86
30K
2.2% of stake
Aug 21No plan
Laura A Williams
Chief Patient Officer · sold 10,739 at avg $3.86
41K
2.8% of stake
Aug 21No plan
Michael Raab
President & CEO · sold 58,574 at avg $3.86
226K
3.4% of stake
Aug 21No plan
John E Bishop
See Remarks · sold 19,750 at avg $3.86
76K
5.9% of stake
Jul 1510b5-1 plan
Michael Raab
President & CEO · sold 41,668 at $5.06
211K
2.4% of stake
Jun 1810b5-1 plan
Laura A Williams
Chief Patient Officer · sold 81,898 at $5.99
491K
18% of stake
Jun 1510b5-1 plan
Michael Raab
President & CEO · sold 41,666 at $5.67
236K
2.4% of stake
May 21No plan
Susan Hohenleitner
Chief Financial Officer · sold 1,455 at $6.27
9K
0.6% of stake
May 21No plan
James Parker Brady
Chief Human Resources Officer · sold 1,846 at $6.27
12K
0.7% of stake
May 21No plan
Joseph James Reilly
See Remarks · sold 3,719 at avg $6.27
23K
2.4% of stake
May 21No plan
Eric Duane Foster
Chief Commercial Officer · sold 7,998 at avg $6.27
50K
1.9% of stake
May 21No plan
Mike Kelliher
Chief Business Officer · sold 7,248 at avg $6.27
45K
2.0% of stake
May 21No plan
Laura A Williams
Chief Patient Officer · sold 6,989 at avg $6.27
44K
1.6% of stake
May 21No plan
Michael Raab
President & CEO · sold 54,748 at avg $6.27
343K
3.0% of stake
May 21No plan
John E Bishop
See Remarks · sold 2,306 at $6.27
14K
0.7% of stake
May 1510b5-1 plan
Michael Raab
President & CEO · sold 41,666 at $6.28
262K
2.3% of stake
Apr 1510b5-1 plan
Michael Raab
President & CEO · sold 41,668 at $6.29
262K
2.2% of stake
Mar 1610b5-1 plan
Michael Raab
President & CEO · sold 41,666 at $5.84
243K
2.2% of stake
Feb 2410b5-1 plan
Michael Raab
President & CEO · sold 41,666 at $6.26
261K
2.2% of stake
Feb 20
David M Mott
Director · bought 333,333 at $5.84
$1.95M
11% of stake
Feb 20No plan
John E Bishop
See Remarks · sold 3,179 at avg $5.85
19K
0.9% of stake
Feb 20No plan
Joseph James Reilly
See Remarks · sold 4,991 at avg $5.85
29K
3.2% of stake
Feb 20No plan
Laura A Williams
See Remarks · sold 8,176 at avg $5.85
48K
1.8% of stake
Feb 20No plan
Susan Hohenleitner
Chief Financial Officer · sold 2,033 at avg $5.85
12K
0.9% of stake
Feb 20No plan
James Parker Brady
Chief Human Resources Officer · sold 2,543 at avg $5.85
15K
1.0% of stake
Feb 20No plan
Mike Kelliher
See Remarks · sold 9,595 at avg $5.85
56K
2.6% of stake
Feb 20No plan
Michael Raab
President & CEO · sold 45,982 at avg $5.85
269K
2.4% of stake
Feb 20No plan
Eric Duane Foster
Chief Commercial Officer · sold 10,439 at avg $5.85
61K
2.4% of stake
Jan 810b5-1 plan
Laura A Williams
Chief Patient Officer · sold 50,000 at $6.98
349K
12% of stake
Nov 21, 2025No plan
Elizabeth A Grammer
See Remarks · sold 5,995 at $5.54
33K
2.0% of stake
Nov 21, 2025No plan
Michael Raab
President & CEO · sold 46,887 at $5.54
260K
3.1% of stake
Nov 21, 2025No plan
Mike Kelliher
See Remarks · sold 5,560 at $5.54
31K
2.0% of stake
Nov 21, 2025No plan
Laura A Williams
Chief Patient Officer · sold 6,426 at $5.54
36K
1.8% of stake
Nov 21, 2025No plan
Eric Duane Foster
Chief Commercial Officer · sold 5,814 at $5.54
32K
1.9% of stake
Nov 21, 2025No plan
Joseph James Reilly
See Remarks · sold 11,086 at $5.54
61K
9.2% of stake
Aug 26, 202510b5-1 plan
Laura A Williams
Chief Patient Officer · sold 80,000 at avg $6.12
490K
18% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ARDX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ARDX

CompareIntrinsic value

ARQTArcutis Biotherapeutics Inc.

$34.05+6.41%65

CRMDCorMedix Inc.

$5.66+1.80%84

ORGOOrganogenesis Holdings Inc.

$0.87+4.19%50

LQDALiquidia Corporation

$47.38+12.27%72

ZLABZai Lab Ltd

$22.80+3.83%40

NATRNature's Sunshine Products Inc.

$12.84+6.38%70

INVAInnoviva Inc.

$21.26+1.58%56

VREOFVireo Growth Inc.

$7.29-2.15%30

Held by ETFs

ARDX is in 33 US ETFs. The largest of them, with ARDX's weight in each:

Spot a number that looks wrong? Check it in ARDX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ARDX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.